Genetic reduction in ANGPTL3 and ANGPTL4 is associated with lower risk of chronic kidney disease (CKD) via enhanced lipoprotein lipase (LPL) activity, according to results of a drug target Mendelian randomisation (MR) study and single cell RNA sequencing analyses.
ANGPTL3 loss of function accelerates TRL lipolysis pathway
Fresh mechanistic insights into the impact of profound ANGPTL3 deficiency are provided in a study of apoB48, apoB100 and TG metabolism in chylomicrons, VLDL1, VLDL2, IDL and LDL in individuals with ANGPTL3 homozygous or heterozygous loss of function (LOF) variants, compared with controls.
The evaluation of postprandial triglycerides: Relevance to metabolic disease and cardiovascular risk
The fasting lipid profile does not necessarily illustrate the dynamic features of lipid metabolism over a 24 hour period as human subjects are in the postprandial (PP) state for most of the day. PP triglyceride (TG) measurement in plasma has been reported to have advantages compared to fasting TG in terms of practicality and the ability to predict cardiovascular risk.
Topline SHASTA-3 and SHASTA-4 results show durable TG reductions with plozasiran
The Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridaemia (sHTG) have met their primary endpoint of TG reduction versus placebo and all prespecified secondary endpoints, including a statistically significant reduction in acute pancreatitis (AP) compared to placebo.
Residual risk beyond LDL: A new apoB-centred framework for atherosclerosis
Professor Jan Borén, Institute of Medicine, University of Gothenburg, Sweden, welcomes the timely reframing of apoB biology presented in Professor Chris Packard’s video presentation ‘ApoB and atherosclerosis 2026: Answers and Questions‘, highlighting its importance in moving the field beyond the LDL-centric model to a more integrated view which includes the atherogenic potential and clinical significance of triglyceride-rich lipoproteins and Lp(a).
Risk weighted apoB improves CHD risk stratification
Risk weighted apoB (RW-apoB), a novel measure that integrates the particle number and atherogenic potential of LDL, triglyceride rich lipoprotein (TRL) and Lp(a), more accurately reflects total atherogenic burden and coronary heart disease (CHD) risk than LDL-C, non-HDL-C or apoB alone. This is the conclusion of Professor Jan Borén and colleagues from results with the […]
